Palbociclib

Palbociclib capsules, the English name is Palbociclib, and the trade name is Ibrance. This is an oral cyclin-dependent kinase (CDKs) 4 and 6 inhibitor. CDKs 4 and 6 are key regulators of the cell cycle, triggering cell cycle progression. Aibexin’s approved indication in the United States is for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors. As initial endocrine therapy in postmenopausal women. As of 2018, it has been approved for marketing in 86 countries and regions around the world, with China being the 87th.